OBO ID: DOID:0080422

Citations

(18 total)

Term: Dravet syndrome

Banerji, R., Huynh, C., Figueroa, F., Dinday, M.T., Baraban, S.C., Patel, M. (2021) Enhancing glucose metabolism via gluconeogenesis is therapeutic in a zebrafish model of Dravet syndrome. Brain communications. 3:fcab004

Sturgeon, M.L., Langton, R., Sharma, S., Cornell, R.A., Glykys, J., Bassuk, A.G. (2021) The opioid antagonist naltrexone decreases seizure-like activity in genetic and chemically induced epilepsy models. Epilepsia open. 6:528-538

Tiraboschi, E., Martina, S., van der Ent, W., Grzyb, K., Gawel, K., Cordero-Maldonado, M.L., Poovathingal, S.K., Heintz, S., Satheesh, S.V., Brattespe, J., Xu, J., Suster, M., Skupin, A., Esguerra, C.V. (2020) New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndrome. Epilepsia. 61(3):549-560

Weuring, W.J., Singh, S., Volkers, L., Rook, M.B., van 't Slot, R.H., Bosma, M., Inserra, M., Vetter, I., Verhoeven-Duif, N.M., Braun, K.P.J., Rivara, M., Koeleman, B.P.C. (2020) NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet Syndrome. PLoS One. 15:e0219106

Brenet, A., Hassan-Abdi, R., Somkhit, J., Yanicostas, C., Soussi-Yanicostas, N. (2019) Defective Excitatory/Inhibitory Synaptic Balance and Increased Neuron Apoptosis in a Zebrafish Model of Dravet Syndrome. Cells. 8(10):

Griffin, A.L., Jaishankar, P., Grandjean, J.M., Olson, S.H., Renslo, A.R., Baraban, S.C. (2019) Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome. Brain communications. 1:fcz008

Sourbron, J., Partoens, M., Scheldeman, C., Zhang, Y., Lagae, L., de Witte, P. (2019) Drug repurposing for Dravet syndrome in scn1Lab^-/- mutant zebrafish. Epilepsia. 60(2):e8-e13

Varga, M., Ralbovszki, D., Balogh, E., Hamar, R., Keszthelyi, M., Tory, K. (2018) Zebrafish Models of Rare Hereditary Pediatric Diseases. Diseases (Basel, Switzerland). 6(2)

Griffin, A., Hamling, K.R., Knupp, K., Hong, S., Lee, L.P., Baraban, S.C. (2017) Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain : a journal of neurology. 140(3):669-683

Grone, B.P., Qu, T., Baraban, S.C. (2017) Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome.. eNeuro. 4(4)

Sourbron, J., Smolders, I., de Witte, P., Lagae, L. (2017) Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish.. Frontiers in pharmacology. 8:191

Kumar, M.G., Rowley, S., Fulton, R., Dinday, M.T., Baraban, S.C., Patel, M. (2016) Altered Glycolysis and Mitochondrial Respiration in a Zebrafish Model of Dravet Syndrome. eNeuro. 3(2):e0008-16

Sourbron, J., Schneider, H., Kecskés, A., Liu, Y., Buening, E.M., Lagae, L., Smolders, I., de Witte, P.A. (2016) Serotonergic Modulation as Effective Treatment for Dravet syndrome in a Zebrafish Mutant Model. ACS Chemical Neuroscience. 7(5):588-98

Berio, A., Piazzi, A. (2015) Activity of drugs and components of natural origin in the severe myoclonic epilepsy of infancy (Dravet syndrome). Central nervous system agents in medicinal chemistry. 15(2):95-8

Dinday, M.T., Baraban, S.C. (2015) Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome(1,2,3). eNeuro. 2(4)

Zhang, Y., Kecskés, A., Copmans, D., Langlois, M., Crawford, A.D., Ceulemans, B., Lagae, L., de Witte, P.A., Esguerra, C.V. (2015) Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine. PLoS One. 10:e0125898

Baraban, S.C., Dinday, M.T., and Hortopan, G.A. (2013) Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nature communications. 4:2410

Suls, A., Jaehn, J.A., Kecskés, A., Weber, Y., Weckhuysen, S., Craiu, D.C., Siekierska, A., Djémié, T., Afrikanova, T., Gormley, P., von Spiczak, S., Kluger, G., Iliescu, C.M., Talvik, T., Talvik, I., Meral, C., Caglayan, H.S., Giraldez, B.G., Serratosa, J., Lemke, J.R., Hoffman-Zacharska, D., Szczepanik, E., Barisic, N., Komarek, V., Hjalgrim, H., Møller, R.S., Linnankivi, T., Dimova, P., Striano, P., Zara, F., Marini, C., Guerrini, R., Depienne, C., Baulac, S., Kuhlenbäumer, G., Crawford, A.D., Lehesjoki, A.E., de Witte, P.A., Palotie, A., Lerche, H., Esguerra, C.V., De Jonghe, P., and Helbig, I. (2013) De Novo Loss-of-Function Mutations in CHD2 Cause a Fever-Sensitive Myoclonic Epileptic Encephalopathy Sharing Features with Dravet Syndrome. American journal of human genetics. 93(5):967-975